Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis.
We studied tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) levels in plasma and peritoneal effluent in 10 children on continuous ambulatory peritoneal dialysis (CAPD) before, and 8 and 12 weeks after, treatment with recombinant human erythropoietin (rHuEPO). Plasma t-PA and PAI-1 levels were lower in patients than in controls during the study. The plasma t-PA levels were increased by rHuEPO treatment. Although PAI-1 levels showed a tendency to increase in the early phase of rHuEPO treatment, they later returned to near baseline levels. Peritoneal effluent t-PA levels were decreased at week 8 of treatment, but returned to baseline levels at week 12. Peritoneal effluent PAI-1 levels were not changed by the rHuEPO treatment. No correlation was observed between levels of t-PA and PAI-1 in plasma and in peritoneal effluent. No correlation was seen between plasma PAI-1 levels and duration of CAPD. A significant negative correlation was found between the plasma PAI-1 levels and hemoglobin levels at week 8 and week 12. These results suggest that plasma t-PA levels can be increased by rHuEPO treatment, while plasma PAI-1 levels are associated with hemoglobin levels.
Gündüz
Z
Z
Department of Pediatric Nephrology, Medical Faculty, Erciyes University, Kayseri, Turkey.
Kisaarslan
F A
FA
Düsünsel
R
R
Poyrazoglu
H M
HM
Saraymen
R
R
Per
H
H
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory; D015849:Plasminogen Inactivators / Q000032:analysis*; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator / Q000032:analysis*
D015849:Plasminogen Inactivators; D011994:Recombinant Proteins; D004921:Erythropoietin; D010959:Tissue Plasminogen Activator